ISSN: 2213-8587

Journal Home

Journal Guideline

The Lancet Diabetes and Endocrinology Q1 Unclaimed

Elsevier Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Lancet Diabetes and Endocrinology is a journal indexed in SJR in Endocrinology and Endocrinology, Diabetes and Metabolism with an H index of 173. It has an SJR impact factor of 10,247 and it has a best quartile of Q1. It has an SJR impact factor of 10,247.

The Lancet Diabetes and Endocrinology focuses its scope in these topics and keywords: diabetes, type, patients, disease, change, digestto, drugscorrection, drugssglt, early, hypopituitarism, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Endocrinology (Q1) Endocrinology, Diabetes and Metabolism (Q1) Endocrinology, Diabetes and Metabolism (Q1) Internal Medicine (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

10,247

SJR Impact factor

173

H Index

194

Total Docs (Last Year)

575

Total Docs (3 years)

4605

Total Refs

7030

Total Cites (3 years)

222

Citable Docs (3 years)

12.48

Cites/Doc (2 years)

23.74

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Endocrine Reviews Q1
Nature Reviews Endocrinology Q1
Nature Metabolism Q1
Diabetes Care Q1
Bone Research Q1

Compare this journals

Aims and Scope

Best articles by citations

Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial

An artistic awakening

Endocrinology in focus: photo competition 2015

I'll have what they're having

The Look AHEAD study: a missed opportunity

The Look AHEAD study: a missed opportunity -Authors' Reply

The Look AHEAD study: a missed opportunity -Editors' Reply

Body language

Marching for endometriosis awareness

Tumoral calcinosis in chronic renal failure

Excess deaths in women with type 1 diabetes: time to act

Screening for differentiated thyroid cancer in selected populations

SHOW MORE ARTICLES

Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial

The proliferation of irrational metformin fixed-dose combinations in India

New traditions in Middle Eastern hospitality

Association between 25-hydroxyvitamin D and type 2 diabetes

Metyrapone stimulation test to diagnose central adrenal insufficiency

Effectiveness of an mHealth intervention to improve the cardiometabolic profile of people with prehypertension in low-resource urban settings in Latin America: a randomised controlled trial

Endemic diabetes in the world's poorest people

Weight loss: slow and steady does not win the race

Use of national data sources in diabetes epidemiology

ALTITUDE: defining a ceiling for blockade of the renin-angiotensin system?

Dying for a good night's sleep

Leptin: 20 years later